NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE150956 Query DataSets for GSE150956
Status Public on Jul 15, 2020
Title Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis
Organism Homo sapiens
Experiment type Non-coding RNA profiling by high throughput sequencing
Summary We analyzed cell-free microRNAs (cfmiRs) in blood, tissue, and urine samples of melanoma patients to find potential biomarkers for monitoring and assessing early detection of melanoma metastasis. This study demonstrates that identifying cfmiR signatures in body fluids may allow for detection and assessment of melanoma brain metastasis (MBM) and metastatic melanoma patients undergoing checkpoint inhibitor immunotherapy treatments.
 
Overall design Data was extracted from patients' blood, urine, and tissue. Samples were profiled for cfmiRs by using a next generation sequencing (NGS) probe-based HTG EdgeSeq miRNA whole transcriptome assay. 2083 microRNAs were profiled for 409 clinical specimens. Normal (cancer-free) donor plasma (n=48) and serum plasma (n=48) samples were analyzed in duplicates. Pre-surgery plasma from melanoma brain metastasis patients (MBM, n=36) were compared for differences in their cfmiR counts, and then verified in a second cohort of MBM plasma samples (n = 24). A cfmiR signature was identified in MBM plasma samples, and further verified in MBM tumor tissues (n=24). MBM cfmiR signature was specifically compared to patients with other cancer types that had brain metastasis (LuBM, n=6 and BCBM, n=7) and glioblastomas (n=36). In addition, the detection of cfmiRs in pre- and post-treatment plasma (n=20) and urine (n=14) samples collected from metastatic melanoma patients receiving checkpoint inhibitor immunotherapy (CII) showed potential utility in assessing CII responses. Normal urine samples (n=8) in duplicates were analyzed to demonstrate reproducibility and compared to urine from metastatic melanoma patients.
 
Contributor(s) Bustos MA, Tran KD, Hoon DB, Rahimzadeh N
Citation(s) 32630542
Submission date May 20, 2020
Last update date Mar 25, 2021
Contact name Dave S.B. Hoon
E-mail(s) [email protected]
Organization name Saint John's Cancer Institute
Department Translational Molecular Medicine
Street address 2200 Santa Monica Boulevard
City Santa Monica
State/province CA
ZIP/Postal code 90403
Country USA
 
Platforms (3)
GPL15520 Illumina MiSeq (Homo sapiens)
GPL16791 Illumina HiSeq 2500 (Homo sapiens)
GPL21697 NextSeq 550 (Homo sapiens)
Samples (404)
GSM4561842 Normal-P1-1
GSM4561843 Normal-P1-10
GSM4561844 Normal-P1-11
Relations
BioProject PRJNA634142
SRA SRP262521

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE150956_MBMvs.LuBm-DESeq2-Normalized.txt.gz 6.2 Kb (ftp)(http) TXT
GSE150956_NormalP_S-DESeq2-Normalized.txt.gz 908.9 Kb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap